Back to News
Market Impact: 0.4
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
Source: zacks.com
Healthcare & BiotechCompany FundamentalsCorporate Guidance & Outlook
Tango Therapeutics shares fell 16.4% despite an 82% response rate and durable disease control in updated pancreatic cancer results. Investors weighed the clinical data against the company's R&D cuts.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
-0.20
Ticker Sentiment
TNGX0.10
More News
- From Wall Street to Silicon Valley, Anthropic IPO poised to have massive 'trickle-down effect'
- Anthropic’s IPO filing shows explosive growth, risks and staggering costs
- EQT becomes the nation’s leading natural gas ‘juggernaut’ with a $13B deal as data center, export demand surges
- Microsoft offers buyouts to nearly 30% of workforce in ongoing AI shift
- Elon Musk warns more than 200 AI cloud companies face ‘guppy-level death’ as the AI boom runs into a debt crisis
- Anthropic’s risk factors include the end of humanity, a feud with the Pentagon, and CEO Dario Amodei’s reputation